Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data ; volume:21 ; number:1 ; day:2 ; month:5 ; year:2019 ; pages:1-11 ; date:12.2019
Arthritis Research & Therapy ; 21, Heft 1 (2.5.2019), 1-11, 12.2019
- Classification
-
Medizin, Gesundheit
- Creator
-
Deodhar, A.
Mease, P. J.
McInnes, I. B.
Baraliakos, X.
Reich, K.
Blauvelt, A.
Leonardi, C.
Porter, B.
Das Gupta, A.
Widmer, A.
Pricop, L.
Fox, T.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-019-1882-2
- URN
-
urn:nbn:de:101:1-2019052122102741132339
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Deodhar, A.
- Mease, P. J.
- McInnes, I. B.
- Baraliakos, X.
- Reich, K.
- Blauvelt, A.
- Leonardi, C.
- Porter, B.
- Das Gupta, A.
- Widmer, A.
- Pricop, L.
- Fox, T.
- SpringerLink (Online service)
Other Objects (12)
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A Review in Psoriatic Arthritis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A Review in Psoriatic Arthritis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A Review in Psoriatic Arthritis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study